Related Experiment Video

Updated: Jun 3, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition

Tze Fang Wong1, Takashi Takeda, Bin Li

  • 1Department of Obstetrics and Gynecology, Sendai, Japan.

Gynecologic Oncology
|April 1, 2011
PubMed
Abstract

Insights

Curcumin effectively inhibits uterine leiomyosarcoma cell growth by targeting the AKT-mTOR pathway. Unlike rapamycin, curcumin also demonstrates a significant pro-apoptotic effect in these cancer cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Uterine leiomyosarcoma exhibits poor response to conventional chemotherapy.
  • Loss of PTEN leads to AKT-mTOR pathway activation, promoting leiomyosarcoma.
  • Curcumin, from Curcuma longa, possesses known antitumor properties.

Purpose of the Study:

  • To investigate the antitumor effects of curcumin on uterine leiomyosarcoma cells.
  • To explore curcumin as a potential alternative to standard chemotherapy.
  • To elucidate the mechanism of curcumin's action on leiomyosarcoma.

Main Methods:

  • In vitro culture of human leiomyosarcoma cell lines (SKN, SK-UT-1).
  • Treatment with varying doses of rapamycin or curcumin.
  • Assessment of cell proliferation (MTS assay), protein phosphorylation (Western Blotting), and apoptosis (Western Blotting, Caspase-3 assay, TUNEL assay).

Main Results:

  • Both rapamycin and curcumin reduced SKN cell proliferation.
  • Curcumin inhibited mTOR, p70S6, and S6 phosphorylation, similar to rapamycin.
  • Curcumin significantly induced apoptosis in SKN cells in a dose-dependent manner, while rapamycin did not.

Conclusions:

  • Curcumin inhibits uterine leiomyosarcoma cell growth by targeting the AKT-mTOR pathway.
  • Curcumin exhibits a pro-apoptotic effect on uterine leiomyosarcoma cells, distinct from rapamycin's effects.
  • Curcumin represents a promising therapeutic agent for uterine leiomyosarcoma.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...